M. Sadarangani and A. J. Pollard, Serogroup B meningococcal vaccines-an unfinished story

, Lancet Infect Dis, vol.10, pp.112-136, 2010.

F. Caron, I. P. Du-chatelet, J. P. Leroy, C. Ruckly, M. Blanchard et al., From tailor-386 made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal 387 meningococcal B outbreak, Lancet Infect Dis, vol.11, pp.455-63, 2011.

D. S. Stephens, Outer-membrane-vesicle vaccines: old but not forgotten, Lancet Infect Dis, vol.389, pp.421-423, 2011.
DOI : 10.1016/s1473-3099(11)70096-2

U. Vogel, M. K. Taha, J. A. Vazquez, J. Findlow, H. Claus et al., Predicted strain 391 coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and 392 quantitative assessment, Lancet Infect Dis, vol.13, pp.416-441, 2013.

D. Medini, M. Stella, and J. Wassil, MATS: Global coverage estimates for 4CMenB, a novel 394 multicomponent meningococcal B vaccine, Vaccine, vol.33, pp.2629-2665, 2015.

J. C. Nagaputra, C. S. Rollier, M. Sadarangani, J. C. Hoe, O. H. Mehta et al.,

E. Wedege, K. Bolstad, A. Aase, T. K. Herstad, L. Mccallum et al., Functional 407 and specific antibody responses in adult volunteers in new zealand who were given one of 408 two different meningococcal serogroup B outer membrane vesicle vaccines, Clin Vaccine, vol.409

, Immunol, vol.14, pp.830-838, 2007.

V. Delbos, L. Lemee, J. Benichou, G. Berthelot, M. K. Taha et al., Meningococcal 411 carriage during a clonal meningococcal B outbreak in France, Eur J Clin Microbiol Infect Dis, vol.412, pp.1451-1460, 2013.

V. Delbos, L. Lemee, J. Benichou, G. Berthelot, A. E. Deghmane et al., , p.414

, MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage

, Vaccine, vol.31, pp.4416-4436, 2013.

F. Caron, V. Delbos, E. Houivet, A. E. Deghmane, J. P. Leroy et al., Evolution of 417 immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer 418 membrane vesicle vaccine MenBvac, Vaccine, vol.30, pp.5059-62, 2012.

E. D. Mcintosh, M. Broker, J. Wassil, J. A. Welsch, and R. Borrow, Serum bactericidal antibody 420 assays -The role of complement in infection and immunity, Vaccine, vol.33, pp.4414-4435, 2015.

R. Borrow, P. Balmer, and E. Miller, Meningococcal surrogates of protection--serum 422 bactericidal antibody activity, Vaccine, vol.23, pp.2222-2229, 2005.

K. A. Jolley, M. S. Chan, and M. C. Maiden, mlstdbNet -distributed multi-locus sequence typing 424 (MLST) databases, BMC Bioinformatics, vol.5, p.86, 2004.

F. Mcquaid, M. D. Snape, T. M. John, S. Kelly, H. Robinson et al., Persistence of 426 specific bactericidal antibodies at 5 years of age after vaccination against serogroup B 427 meningococcus in infancy and at 40 months, CMAJ, vol.187, pp.215-238, 2015.

G. Bjune, E. A. Hoiby, J. K. Gronnesby, O. Arnesen, J. H. Fredriksen et al.,

J. W. Tappero, R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams et al.,

, Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a 433 randomized controlled trial in Chile, Jama, vol.281, pp.1520-1527, 1999.

J. Holst, B. Feiring, L. M. Naess, G. Norheim, P. Kristiansen et al., The concept 435 of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal 436 disease, Vaccine, vol.23, pp.2202-2207, 2005.

V. Thornton, D. Lennon, K. Rasanathan, J. O'hallahan, P. Oster et al., Safety and 438 immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy 439 adults: beginning of epidemic control, Vaccine, vol.24, pp.1395-400, 2006.

K. Sexton, D. Lennon, P. Oster, S. Crengle, D. Martin et al., The New, p.441

, Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating 442 epidemic, N Z Med J, vol.117, p.1015, 2004.

E. Wedege, R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Froholm, Expression of an 444 inaccessible P1.7 subtype epitope on meningococcal class 1 proteins, J Med Microbiol, vol.445, pp.23-31, 1993.

S. N. Ladhani, M. M. Giuliani, A. Biolchi, M. Pizza, K. Beebeejaun et al.,